Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 917-929

  Thakur, Kuldeep Singh ^a   Prakash, Atish ^a   Bisht, Rohit ^a   Bansal, Puneet Kumar ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Candesartan; Haloperidol; Lisinopril; Oxidative damage; Tardive dyskinesia

Indexed keywords

BOVINE SERUM ALBUMIN; CANDESARTAN; CATALASE; GLUTATHIONE; HALOPERIDOL; INTERLEUKIN 1BETA; LISINOPRIL; MALONALDEHYDE; NITRITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR ASSESSMENT; BODY WEIGHT; BRAIN CORTEX; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS STRIATUM; DISSECTION; DRUG ACTIVITY; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; GRIP STRENGTH; HOMOGENATE; LIPID PEROXIDATION; LOCOMOTION; MALE; MONOTHERAPY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; RAT; ROTA ROD ACTIVITY; STEREOTYPY; TARDIVE DYSKINESIA; TREATMENT DURATION; ANIMAL; DRUG EFFECTS; GROOMING; HAND STRENGTH; MASTICATION; MAZE TEST; MEMORY; METABOLISM; MOTOR ACTIVITY; MOVEMENT DISORDERS; PATHOPHYSIOLOGY; ROTAROD TEST; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; BODY WEIGHT; GROOMING; HALOPERIDOL; HAND STRENGTH; INTERLEUKIN-1BETA; LISINOPRIL; MALE; MALONDIALDEHYDE; MASTICATION; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; MOVEMENT DISORDERS; NITRITES; OXIDATIVE STRESS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; STEREOTYPED BEHAVIOR; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84952892556     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313515038     Document Type: Article

References (65)

1. Blanchet PJ,. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30: 101-107.
2. Bishnoi M, Chopra K, Kulkarni SK,. Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 2008; 590: 241-245.
3. Kulkarni SK, Naidu PS,. Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives. Drugs Today (Barc) 2003; 39: 19-49.
4. Bishnoi M, Boparai RK,. An animal model to study the molecular basis of tardive dyskinesia. Methods Mol Biol 2012; 829: 193-201.
5. De Leon J,. The effect of atypical versus typical antipsychotics on tardive dyskinesia: A naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007; 257: 169-172.
6. Klawans HL Jr, Rubovits R,. An experimental model of tardive dyskinesia. J Neural Transm 1972; 33: 235-246.
7. Zhu M, Gu F, Shi J, et al. Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2. Free Radic Biol Med 2008; 45: 1493-1499.
8. Bishnoi M, Chopra K, Kulkarni SK,. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 2007; 59: 181-191.
9. Goff DC, Coyle JT,. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377.
10. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403.
11. Post A, Holsboer F, Behl C,. Induction of NF-kappaB activity during haloperidol induced oxidative toxicity in clonal hippocampal cells: suppression of NFkappaB and neuroprotection by antioxidants. J Neurosci 1998; 18: 8236-8246.
12. Post A, Rücker M, Ohl F, et al. Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002; 26: 397-407.
13. Leung JG, Breden EL,. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011; 45: 525-531.
14. Singh B, Sharma B, Jaggi AS, et al. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: Possible involvement of PPAR-g agonistic property. J Renin Angiotensin Aldosterone Syst 2013; 14: 124-136.
15. Wright JW, Harding JW,. The brain RAS and Alzheimer's disease. Exp Neurol 2010; 223: 326-333.
16. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor perindopril on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352: 176-186.
17. Horiuchi M, Mogi M,. Role of activation of angiotensin II receptor subtypes in ischemic brain damage and cognitive function. Br J Pharmacol 2011; 163: 1122-1130.
18. Labandeira-Garcia JL, Rodriguez-Pallares J, Rodríguez-Perez AI, et al. Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. Am J Neurodegener Dis 2012; 1: 226-244.
19. Lu Q, Zhu YZ, Wong PT,. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 2269-2272.
20. Thoene-Reineke C, Rumschüssel K, Schmerbach K, et al. Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS One 2011; 6: e23646.
21. Garrido-Gilet, al. Involvement of PPAR-gin the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. Journal of Neuroinflammation 2012; 9: 38.
22. Bhateja DK, Dhull DK, Gill A, et al. Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionicacid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms. Eur J Pharmacol 2012; 674: 33-43
23. Pathan AR, Viswanad B, Sonkusare SK, et al. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006; 79: 2209-2216.
24. Naidu PS, Singh A, Kulkarni SK,. Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. Phytother Res 2006; 20: 140-146.
25. Sharma A, Kulkarni SK,. Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 117-125.
26. Kumar P, Kalonia H, Kumar A,. Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: A comparative study. J Psychopharmacol 2011; 25: 1399-1411.
27. Kumar P, Kumar A,. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: A novel nitric oxide mechanism. Food Chem Toxicol 2009; 47: 2522-2530.
28. Butchbach ME, Edwards JD, Burghes AH,. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis 2007; 27: 207-219.
29. Brooks SP, Dunnett SB,. Tests to assess motor phenotype in mice: A user's guide. Nat Rev Neurosci 2009; 10: 519-529.
30. Corti S, Nizzardo M, Nardini M, et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008; 118: 3316-3330.
31. Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120: 1253-1264.
32. Wills ED,. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1966; 99: 667-676.
33. Green LC, Wagner DA, Glagowski J, et al. Analysis of nitrate, nitrite and (15 N) nitrate in biological fluids. Annal Biochem 1982; 126: 131-138.
34. Ellman GL,. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
35. Kono Y,. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978; 186: 189-195.
36. Luck H,. Catalase. In: Bergmeyer HU, (ed) Methods of enzymatic analysis. New York: Academic Press, 1971, pp. 885-893.
37. Gornall AG, Bardawill CT, David MM,. Determination of serum proteins by means of Biuret reaction. J Biol Chem 1949; 177: 751-766.
38. Ishiwari K, Betz A, Weber S, Felsted J, et al. Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: Effects of pimozide (Orap) in rats. Pharmacol Biochem Behav 2005; 80: 351-362.
39. Bishnoi M, Kulkarni SK, Chopra K,. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. Indian J Exp Biol 2009; 47: 91-97.
40. Naidu PS, Singh A, Kulkarni SK,. Carvedilol attenuates neuroleptic-inducedorofacial dyskinesia: Possible antioxidant mechanisms. Br J Pharmacol 2002; 136: 193-200.
41. Gittis AH, Kreitzer AC,. Striatal microcircuitry and movement disorders. Trends Neurosci 2012; 35: 557-564.
42. Lujan R, Ciruela F,. GABAB receptors-associated proteins potential drug targets in neurological disorders? Curr Drug Targets 2012; 13: 129-144.
43. Reifsnyder JW, Tettambel MA,. Conservative approach to tardive dyskinesia-induced neck and upper back pain. J Am Osteopath Assoc 2013; 113: 636-639.
44. Rosengarten H, Quatermain D,. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three and eighteen month old rats. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1047-1054.
45. Savaskan E,. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2005; 2: 29-35.
46. Kumaran D, Udayabanu M, Kumar M, et al. Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience 2008; 155: 626-639.
47. Ciobica A, Bild W, Hritcu L, et al. Brain renin-angiotensin system in cognitive function: Pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109: 171-180
48. Tota S, Kamat PK, Awasthi H, et al. Candesartan improves memory decline in mice: Involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009; 199: 235-240.
49. Inaba S, Iwai M, Furuno M, et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009; 53: 356-362.
50. Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 2011; 342: 143-147.
51. Kim JM, Uehara Y, Choi YJ, et al. Mechanism of attenuation of pro-inflammatory Ang II-induced NF-ΰB activation by genistein in the kidneys of male rats during aging. Biogerontology 2011; 12: 537-550.
52. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76-80.
53. Tuppo EE, Arias HR,. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
54. Haraguchi T, Takasaki K, Naito T, et al. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Neurosci Lett 2009; 464: 151-155.
55. Ismail H, Mitchell R, McFarlane SI, et al. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: Above and beyond blood pressure lowering. Curr Diab Rep 2010; 10: 32-36.
56. Yasar S, Zhou J, Varadhan R, et al. The use of angiotensin converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women. Clin Pharmacol Ther 2008; 84: 119-126.
57. Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
58. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: 5465.
59. Ola MS, Ahmed MM, Abuohashish HM, et al. Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats. Neurochem Res 2013; 38: 1572-1579.
60. Bild W, Hritcu L, Stefanescu C, et al. Inhibition of central angiotensin II enhances memory function and reduces oxidative stress in rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 79-88.
61. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, et al. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J Neurochem 2009; 109: 656-669.
62. Dominguez-Mejjide A, Villar-Cheda B, Garrido-Gil P, et al. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA. Neuropharmacology 2014; 76: 156-168.
63. Gohlke P, Weiss S, Jansen A, et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298: 62-70.
64. Jung KH, Chu K, Lee ST, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051-1058.
65. Sathiya S, Ranju V, Kalaivani P, et al. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Neuropharmacology 2013; 73: 98-110.